这家瑞士公司于周二表示，合同药物制造商龙沙在同意收购德国默克集团（Merck KGaA）位于美国的五处生产基地后，其在美业务规模将扩大一倍以上。
Contract drug manufacturer Lonza will more than double its US footprint after agreeing to buy five manufacturing sites in the country from Merck KGaA , the Swiss company said on Tuesday.
这笔交易将使龙沙在美的工厂数量达到九处，并扩大其细胞和基因治疗能力，而德国默克则继续向集中的生命科学业务组合转型。
The deal will bring the number of Lonza's US sites to nine, and expand its cell and gene therapy capabilities, while Germany's Merck continues its shift towards a concentrated life science portfolio.
两家公司表示，该交易的估值在数亿瑞郎的低至中三位数范围内，预计将于明年年中完成。根据该交易，约有1100名员工将加入龙沙的员工队伍。
The deal is valued in a range of low- to mid-triple-digit million Swiss francs, the companies said, and is expected to close in the middle of next year. Around 1,100 employees are set to join Lonza's workforce under the transaction.
巴克莱分析师将这笔交易形容为对龙沙“具有战略积极意义”，并指出产能利用率和利润率的提升将带来上升空间。
Barclays analysts described the deal as "strategically positive" for Lonza, pointing to upside from utilisation and margin improvement.